The use of interferon for the treatment of viral hepatitis in pediatric liver transplant recipients.

Bakr Nour, A. Tzakis, D. H. Van Thiel

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Between January 1990 and July 1992, 12 children with viral hepatitis occurring after liver transplantation (LTx) were treated with interferon alpha-2b. Seven were female and 5 were male; their ages ranged between 0.7 and 14.7 years (mean = 5.4 years). The indications for LTx included biliary atresia (n = 7), chronic active hepatitis (n = 2), and fulminant hepatitis (n = 3). Therapy was initiated at a dose of 1-3 million units (5 million units/1.73 m2) given 3 times per week and continued for more than six months. Six patients experienced a full response with normalization of their serum liver enzymes and a complete resolution of histologic hepatitis on liver biopsy. Two patients had a partial response with improvement in their liver enzyme values. Four patients required retransplantation for worsening hepatitis despite interferon (IFN) therapy. Three of these four were treated prophylactically with IFN therapy after their second transplant. Two of these four have shown no clinical or histologic evidence of hepatitis in their second liver after a follow-up of 20 and 4 months. IFN failed to prevent recurrent hepatitis in the other two children. One died at retransplant and the second developed recurrence of the giant cell hepatitis and rejection. Overall, IFN was well-tolerated by 11 of the 12 children; the 12th child required a dose reduction because of seizures. Based upon this preliminary uncontrolled experience, we conclude that the use of interferon alpha-2b is safe and effective in the treatment of viral hepatitis in children after liver transplantation.

Original languageEnglish
Pages (from-to)109-113
Number of pages5
JournalJournal - Oklahoma State Medical Association
Volume88
Issue number3
Publication statusPublished - Mar 1995
Externally publishedYes

Fingerprint

Interferons
Hepatitis
Pediatrics
interferon alfa-2b
Liver
Therapeutics
Liver Transplantation
Biliary Atresia
Transplant Recipients
Giant Cells
Enzymes
Chronic Hepatitis
Seizures
Transplants
Biopsy
Recurrence
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The use of interferon for the treatment of viral hepatitis in pediatric liver transplant recipients. / Nour, Bakr; Tzakis, A.; Van Thiel, D. H.

In: Journal - Oklahoma State Medical Association, Vol. 88, No. 3, 03.1995, p. 109-113.

Research output: Contribution to journalArticle

@article{ba999389edae4a768510dee1cf3f17fb,
title = "The use of interferon for the treatment of viral hepatitis in pediatric liver transplant recipients.",
abstract = "Between January 1990 and July 1992, 12 children with viral hepatitis occurring after liver transplantation (LTx) were treated with interferon alpha-2b. Seven were female and 5 were male; their ages ranged between 0.7 and 14.7 years (mean = 5.4 years). The indications for LTx included biliary atresia (n = 7), chronic active hepatitis (n = 2), and fulminant hepatitis (n = 3). Therapy was initiated at a dose of 1-3 million units (5 million units/1.73 m2) given 3 times per week and continued for more than six months. Six patients experienced a full response with normalization of their serum liver enzymes and a complete resolution of histologic hepatitis on liver biopsy. Two patients had a partial response with improvement in their liver enzyme values. Four patients required retransplantation for worsening hepatitis despite interferon (IFN) therapy. Three of these four were treated prophylactically with IFN therapy after their second transplant. Two of these four have shown no clinical or histologic evidence of hepatitis in their second liver after a follow-up of 20 and 4 months. IFN failed to prevent recurrent hepatitis in the other two children. One died at retransplant and the second developed recurrence of the giant cell hepatitis and rejection. Overall, IFN was well-tolerated by 11 of the 12 children; the 12th child required a dose reduction because of seizures. Based upon this preliminary uncontrolled experience, we conclude that the use of interferon alpha-2b is safe and effective in the treatment of viral hepatitis in children after liver transplantation.",
author = "Bakr Nour and A. Tzakis and {Van Thiel}, {D. H.}",
year = "1995",
month = "3",
language = "English",
volume = "88",
pages = "109--113",
journal = "The Journal of the Oklahoma State Medical Association",
issn = "0030-1876",
publisher = "Oklahoma State Medical Association",
number = "3",

}

TY - JOUR

T1 - The use of interferon for the treatment of viral hepatitis in pediatric liver transplant recipients.

AU - Nour, Bakr

AU - Tzakis, A.

AU - Van Thiel, D. H.

PY - 1995/3

Y1 - 1995/3

N2 - Between January 1990 and July 1992, 12 children with viral hepatitis occurring after liver transplantation (LTx) were treated with interferon alpha-2b. Seven were female and 5 were male; their ages ranged between 0.7 and 14.7 years (mean = 5.4 years). The indications for LTx included biliary atresia (n = 7), chronic active hepatitis (n = 2), and fulminant hepatitis (n = 3). Therapy was initiated at a dose of 1-3 million units (5 million units/1.73 m2) given 3 times per week and continued for more than six months. Six patients experienced a full response with normalization of their serum liver enzymes and a complete resolution of histologic hepatitis on liver biopsy. Two patients had a partial response with improvement in their liver enzyme values. Four patients required retransplantation for worsening hepatitis despite interferon (IFN) therapy. Three of these four were treated prophylactically with IFN therapy after their second transplant. Two of these four have shown no clinical or histologic evidence of hepatitis in their second liver after a follow-up of 20 and 4 months. IFN failed to prevent recurrent hepatitis in the other two children. One died at retransplant and the second developed recurrence of the giant cell hepatitis and rejection. Overall, IFN was well-tolerated by 11 of the 12 children; the 12th child required a dose reduction because of seizures. Based upon this preliminary uncontrolled experience, we conclude that the use of interferon alpha-2b is safe and effective in the treatment of viral hepatitis in children after liver transplantation.

AB - Between January 1990 and July 1992, 12 children with viral hepatitis occurring after liver transplantation (LTx) were treated with interferon alpha-2b. Seven were female and 5 were male; their ages ranged between 0.7 and 14.7 years (mean = 5.4 years). The indications for LTx included biliary atresia (n = 7), chronic active hepatitis (n = 2), and fulminant hepatitis (n = 3). Therapy was initiated at a dose of 1-3 million units (5 million units/1.73 m2) given 3 times per week and continued for more than six months. Six patients experienced a full response with normalization of their serum liver enzymes and a complete resolution of histologic hepatitis on liver biopsy. Two patients had a partial response with improvement in their liver enzyme values. Four patients required retransplantation for worsening hepatitis despite interferon (IFN) therapy. Three of these four were treated prophylactically with IFN therapy after their second transplant. Two of these four have shown no clinical or histologic evidence of hepatitis in their second liver after a follow-up of 20 and 4 months. IFN failed to prevent recurrent hepatitis in the other two children. One died at retransplant and the second developed recurrence of the giant cell hepatitis and rejection. Overall, IFN was well-tolerated by 11 of the 12 children; the 12th child required a dose reduction because of seizures. Based upon this preliminary uncontrolled experience, we conclude that the use of interferon alpha-2b is safe and effective in the treatment of viral hepatitis in children after liver transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0029262829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029262829&partnerID=8YFLogxK

M3 - Article

C2 - 7760205

AN - SCOPUS:0029262829

VL - 88

SP - 109

EP - 113

JO - The Journal of the Oklahoma State Medical Association

JF - The Journal of the Oklahoma State Medical Association

SN - 0030-1876

IS - 3

ER -